PTJ
AKRO

Paul Tudor Jones’s Akero Therapeutics AKRO Stock Holding History

Paul Tudor Jones’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,356
Closed -$2.44M – 3444
2025
Q3 		$2.44M Buy
51,356
+46,682
+999% +$2.26M ﹤0.01% 1677
2025
Q2 		$249K Sell
4,674
-40,327
-90% -$1.83M ﹤0.01% 2981
2025
Q1 		$1.82M Buy
45,001
+10,207
+29% +$433K 0.01% 1414
2024
Q4 		$968K Buy
34,794
+160
+0.5% +$4.85K ﹤0.01% 1752
2024
Q3 		$994K Buy
34,634
+315
+0.9% +$8.21K ﹤0.01% 1622
2024
Q2 		$805K Sell
34,319
-1,876
-5% -$40.1K ﹤0.01% 1574
2024
Q1 		$914K Buy
+36,195
New +$869K 0.01% 1375
2023
Q4 		– Sell
-31,881
Closed -$1.61M – 2320
2023
Q3 		$1.61M Buy
+31,881
New +$1.48M 0.02% 1042
2023
Q2 		– Sell
-36,885
Closed -$1.41M – 2382
2023
Q1 		$1.41M Buy
36,885
+13,887
+60% +$619K 0.02% 983
2022
Q4 		$1.26M Buy
22,998
+10,852
+89% +$465K 0.02% 942
2022
Q3 		$414K Buy
+12,146
New +$186K 0.01% 1537

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Paul Tudor Jones's AKRO Position: Q4 2025 in Review

Paul Tudor Jones sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 51,356 shares — an estimated $2.44M sold.

Paul Tudor Jones first reported a position in AKRO in Q3 2022 and held it in 11 quarters. The position peaked at $2.44M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Paul Tudor Jones reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 51,356 Akero Therapeutics shares in Q4 2025, an estimated $2.44M.
  • Paul Tudor Jones first reported a position in Akero Therapeutics in Q3 2022 and held it in 11 quarters.
  • Paul Tudor Jones's Akero Therapeutics position peaked at $2.44M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Tudor Investment Corp's 13F filing for Q4 2025, filed 17 Feb 2026.